StockNews.AI
AVDL
StockNews.AI
19 days

Avadel Pharmaceuticals to Provide a Corporate Update and Report Second Quarter 2025 Financial Results on August 7

1. Avadel Pharmaceuticals will host a Q2 financial results call on August 7. 2. The call will provide a corporate update and discussion of AVDL's performance. 3. LUMRYZ™, Avadel's FDA-approved product, targets narcolepsy treatment. 4. The webcast will be available for replay on Avadel's website for 90 days.

3m saved
Insight
Article

FAQ

Why Bullish?

Upcoming financial results could potentially showcase positive growth, similar to past earnings occasions when AVDL demonstrated strong performance following key announcements.

How important is it?

The earnings call is crucial for investor insights and could reveal new growth or challenges.

Why Short Term?

Financial results will likely influence market perception immediately, reflecting investor sentiment in the short term.

Related Companies

VRTXNDAQVRTXSNY
July 31, 2025 08:00 ET  | Source: Avadel Pharmaceuticals plc DUBLIN, Ireland, July 31, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, August 7, 2025, to provide a corporate update and discuss the Company's financial results for the second quarter ended June 30, 2025. A live audio webcast of the call can be accessed by visiting the investor relations section of the Company’s website, www.avadel.com. A replay of the webcast will be archived on Avadel’s website for 90 days following the event. Participants may register for the conference call here and are advised to do so at least 10 minutes prior to joining the call. About Avadel Pharmaceuticals plc Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Avadel’s commercial product, LUMRYZ™, was approved by the U.S. Food & Drug Administration (FDA) as the first and only once-at-bedtime oxybate for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years and older with narcolepsy. For more information, please visit www.avadel.com. Investor Contact:Austin Murtagh Precision AQAustin.Murtagh@precisionAQ.com (212) 698-8696 Media Contact:Alyssa RamirezReal Chemistryaramirez@realchemistry.com 

Related News